News

October 5, 2026
Harrow Closes Acquisition of TYRVAYA®
September 30, 2026
Harrow Ophthalmic Portfolio Highlighted in 15 Scientific Presentations at AAOpt and AAO
September 1, 2026
Harrow to Participate in Three Investor Conferences in September 
August 20, 2026
Harrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal Injections
August 10, 2026
Harrow Announces Second Quarter 2026 Financial Results
August 6, 2026
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
July 27, 2026
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
July 20, 2026
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026